This page contains a Flash digital edition of a book.
Neurodegenerative Disease Parkinson's Disease


30. Takatsu H, Nishida H, Matsuo H, et al., Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG, J Nucl Med, 2000;41:71–7.


31. Barbour R, Kling K, Anderson JP, et al., Red blood cells are the major source of alpha-synuclein in blood, Neurodegener Dis, 2008;5:55–9.


32. Braune S, The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes, Clin Auton Res, 2001;11:351–5.


33. Sauvageot N, Vaillant M, Diederich NJ, Reduced sympathetically driven heart rate variability during sleep in Parkinson's disease: a case-control polysomnography-based study, Mov Disord, 2011;26:234–40.


34. Zakrzewska-Pniewska B, Jamrozik Z, Are electrophysiological autonomic tests useful in the assessment of dysautonomia in Parkinson's disease?, Parkinsonism Relat Disord, 2003;9:179–83.


35. Leentjens AF, Van den Akker M, Metsemakers JF, et al., Higher incidence of depression preceding the onset of Parkinson's disease: a register study, Mov Disord, 2003;18:414–8.


36. Shiba M, Bower JH, Maraganore DM, et al., Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study, Mov Disord, 2000;15:669–77.


37. Aarsland D, Bronnick K, Larsen JP, et al., Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study, Neurology, 2009;72:1121–6.


38. Muller A, Reichmann H, Livermore A, et al., Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow- up of de-novo IPD patients, J Neural Transm, 2002;109:805–11.


39. Diederich NJ, Pieri V, Hipp G, et al., Discriminative power of different nonmotor signs in early Parkinson's disease. A case-control study, Mov Disord, 2010;25:882–7.


40. Valappil RA, Black JE, Broderick MJ, et al., Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease, Mov Disord, 2010;25:2296–2303.


41. Hauser RA, Grosset DG, [(123) I]FP-CIT (DaTscan) SPECT Brain


Imaging in Patients with Suspected Parkinsonian Syndromes, J Neuroimaging, 2011 [Epub ahead of print].


42. Marek K, Jennings D, Can we image premotor Parkinson disease?, Neurology, 2009;72(Suppl. 7):S21–6.


43. Marek K, Jennings D, Tamagnan G, et al., Biomarkers for Parkinson's [corrected] disease: tools to assess Parkinson's disease onset and progression, Ann Neurol, 2008;64(Suppl. 2):S111–21.


44. Catafau AM, Tolosa E, Group DCUPSS, Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes, Mov Disord, 2004;19:1175–82.


45. Tolosa E, Borght TV, Moreno E, et al., Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study, Mov Disord, 2007;22:2346–51.


46. Eckert T, Tang C, Ma Y, et al., Abnormal metabolic networks in atypical parkinsonism, Mov Disord, 2008;23:727–33.


47. Behnke S, Berg D, Naumann M, et al., Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound, J Neurol Neurosurg Psychiatry, 2005;76:423–5.


48. Shulman JM, De Jager PL, Feany MB, Parkinson's disease: genetics and pathogenesis, Annu Rev Pathol, 2011;6:193–222.


49. Hardy J, Genetic analysis of pathways to Parkinson disease, Neuron, 2010;68:201–6.


50. Gasser T, Genomic and proteomic biomarkers for Parkinson disease, Neurology, 2009;72(Suppl. 7):S27–31.


51. Nalls MA, Plagnol V, Hernandez DG, et al., Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies, Lancet, 2011;377:641–9.


52. Hong Z, Shi M, Chung KA, et al., DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 2010;133:713–26.


53. Shi M, Bradner J, Hancock AM, et al., Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Ann Neurol, 2011;69:570–80.


54. Henchcliffe C, Beal MF, Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis, Nat Clin Pract Neurol, 2008;4:600–9.


55. Bogdanov M, Matson WR, Wang L, et al., Metabolomic profiling to develop blood biomarkers for Parkinson's disease, Brain, 2008;131:389–96.


56. Johansen KK, Wang L, Aasly JO, et al., Metabolomic profiling in LRRK2-related Parkinson's disease, PLoS One, 2009;4:e7551.


57. Seet RC, Lee CY, Lim EC, et al., Oxidative damage in Parkinson disease: Measurement using accurate biomarkers, Free Radic Biol Med, 2010;48:560–6.


58. Stephenson R, Siderowf A, Stern MB, Premotor Parkinson's disease: clinical features and detection strategies, Mov Disord, 2009;24(Suppl. 2):S665–70.


59. Mueller SG, Weiner MW, Thal LJ, et al., Ways toward an early diagnosis in Alzheimer's disease: The Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimers Dement, 2005;1:55–66.


60. Ueki A, Otsuka M, Life style risks of Parkinson's disease: association between decreased water intake and constipation, J Neurol, 2004;251(Suppl. 7):vII18–23.


61. Goetze O, Wieczorek J, Mueller T, et al., Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test, Neurosci Lett, 2005;375:170–3.


62. Giladi N, Treves TA, Paleacu D, et al., Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease, J Neural Transm, 2000;107:59–71.


63. Tadaiesky MT, Dombrowski PA, Figueiredo CP, et al., Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease, Neuroscience, 2008;156:830–40.


64. Bronner G, Royter V, Korczyn AD, et al., Sexual dysfunction in Parkinson's disease, J Sex Marital Ther, 2004;30:95–105.


65. Schenck CH, Bundlie SR, Mahowald MW, Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder, Neurology, 1996;46:388–93.


20


US NEUROLOGY


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76